| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
RESEARCH AND PRACTICE |
The authors are with the Department of Health Care Policy, Harvard Medical School, Boston, Mass. Philip S. Wang is also with the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School.
Correspondence: Requests for reprints should be sent to Philip S. Wang, MD, DrPH, Department of Health Care Policy, 180 Longwood Ave, Boston, MA 02115 (e-mail: pwang{at}rics.bwh.harvard.edu).
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONReferences |
|---|
Objectives. The purpose of this study was to assess the prevalence and correlates of treatment for serious mental illness.
Methods. Data were derived from the National Comorbidity Survey, a cross-sectional, nationally representative household survey assessing the presence and correlates of mental disorders and treatments. Crude and adjusted likelihoods of receiving treatment for serious mental illness in the previous 12 months were calculated.
Results. Forty percent of respondents with serious mental illness had received treatment in the previous year. Of those receiving treatment, 38.9% received care that could be considered at least minimally adequate, resulting in 15.3% of all respondents with serious mental illness receiving minimally adequate treatment. Predictors of not receiving minimally adequate treatment included being a young adult or an African American, residing in the South, being diagnosed as having a psychotic disorder, and being treated in the general medical sector.
Conclusions. Inadequate treatment of serious mental illness is an enormous public health problem. Public policies and cost-effective interventions are needed to improve both access to treatment and quality of treatment.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONReferences |
|---|
Few empiric data exist on patterns of treatment among people with serious mental illness. Through the use of data from the National Comorbidity Survey (NCS) and the Epidemiologic Catchment Area Study, it has been estimated that roughly half of those with serious mental illness receive some form of treatment in a given year.1,2,8 Although this estimate is disturbingly low, the effective treatment rate could be even lower. A growing body of literature suggests that mental health treatments, if they are to be effective, must conform with evidence-based guidelines regarding type of treatment, intensity of treatment, and duration of treatment.9–13 Previous studies have shown that a substantial proportion of people in treatment for mental disorders do not receive minimally acceptable care.14–17 It is not implausible that the same is true for the subset of patients with serious mental illness.
The present study was undertaken to address 2 aims. First, we sought to use a large, nationally representative general population survey to estimate the proportion of people with serious mental illness who receive care consistent with available evidence-based treatment recommendations.18–23 Second, we sought to identify correlates of receiving any treatment and receiving minimally adequate treatment. Identifying such correlates is a critical first step in developing and targeting interventions to improve the appropriateness of care and health outcomes of those with serious mental illness.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONReferences |
|---|
Part 2 was administered to all respondents who screened positive for any disorder in part 1 (98.1% conditional response rate), all other respondents aged 15 to 24 years (99.4%), and a random subsample of other respondents (99.0%) (a total of 5877 respondents). Part 2 assessed additional disorders, role impairments, and treatments received. The current report is based on the part 2 sample. So that data would be representative of the overall US population, they were weighted to reflect differential probabilities of selection and differential nonresponse rates.
Measures
Serious mental illness.
Public Law 102-321 defines serious mental illness as the presence of any DSM mental disorder, substance use disorder, or developmental disorder that leads to "substantial interference" with "one or more major life activities." The diagnostic component of this definition was operationalized in the NCS with CIDI diagnoses of 3 broad classes of 12-month DSM-III-R disorders: mood disorders (major depression, dysthymia, bipolar disorder), anxiety disorders (panic disorder, generalized anxiety disorder, phobias, posttraumatic stress disorder), and nonaffective psychoses (schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, and psychotic disorder not otherwise specified).
Clinical reappraisal studies documented acceptable to good concordance between most of these diagnoses and blind clinical reinterviews using the Structured Clinical Interview for DSM-III-R as the validation standard.27,28 Exceptions were mania29 and nonaffective psychosis,30 both of which were overdiagnosed by the CIDI according to clinical reinterviews. We addressed overdiagnosis of mania by confining assigned CIDI diagnoses to the euphoric–grandiose subtype of mania, which was assessed with good validity in the NCS. Overdiagnosis of nonaffective psychosis was addressed by carrying out clinical reinterviews with all NCS respondents who screened positive for nonaffective psychosis according to the CIDI and basing final diagnoses on these clinical assessments rather than the original CIDI classifications.
Respondents who met criteria for one of these 12-month CIDI disorders were defined as having serious functional impairment if their disorder was associated with vocational incapacity (as indicated by either inability to hold a job or frequent work absence owing to mental health problems), serious interpersonal difficulties (as indicated by either social isolation or frequent interpersonal difficulties), or a suicide plan or attempt within the previous 12 months or if their disorder met criteria for a "severe mental illness" as operationalized by the National Advisory Mental Health Council of the National Institute of Mental Health.8 The operationalization of serious mental illness has been discussed in more detail elsewhere.1,2
Mental health care sectors. Mental health care in the 12 months before the survey was divided into care received in 5 sectors: (1) general medical sector (seeing a medical doctor other than a psychiatrist in any setting for a mental or emotional problem); (2) psychiatry sector (seeing a psychiatrist for treatment of a mental health problem); (3) nonpsychiatry, mental health specialty sector (seeing a psychologist, social worker, therapist, or counselor for a mental health problem); (4) human services sector (seeing a non–health care professional such as a minister, priest, rabbi, or spiritual advisor for a mental or emotional problem); and (5) self-help sector (participating in a formal self-help or mutual assistance group not run by a professional for a mental or emotional problem). The psychiatry and nonpsychiatry specialty mental health sectors were aggregated to form a category labeled mental health specialty.
Minimally adequate mental health care. We used available evidence-based treatment guidelines for primary care18 and specialty mental health providers19–23 to create working definitions (described elsewhere14,17) of minimally adequate treatment. Minimally adequate treatment during the previous 12 months was defined as follows: (1) receipt of a prescription for an appropriate medication (antidepressant or mood stabilizer for mood disorders; antidepressant or anxiolytic for anxiety disorders; antipsychotic medication for nonaffective psychoses), in combination with 4 or more visits for a mental health problem with a psychiatrist, general medical doctor, or other medical doctor, or (2) among respondents who were not psychotic, 8 or more visits for a mental health problem with either a psychiatrist or another type of mental health specialist.
On the basis of our observation that 4 or more visits for follow-up and medication monitoring are generally recommended during the acute and continuation phases of treatment for mood, anxiety, and psychotic disorders in evidence-based treatment guidelines, a minimum of 4 visits was required for patients receiving medication.18–23 For mood and anxiety disorders, the decision to require 8 or more visits to a mental health specialist in the absence of appropriate medication was based on the observation that time-limited psychotherapies with documented efficacy in treating mood or anxiety disorders have generally required at least 8 sessions in clinical trials.18–20,22,23
Statistical Analysis
The percentages of subjects with individual disorders and serious mental illness who received any mental health care as well as minimally adequate treatment were calculated for the entire study population and for those receiving care in particular health sectors. Bivariate and multivariate logistic regression analyses were used to study associations between sociodemographic covariates and 3 outcomes: (1) receipt of mental health care in any sector among those with serious mental illness, (2) receipt of minimally adequate care among those receiving any mental health care for serious mental illness, and (3) lack of receipt of minimally adequate care among those with serious mental illness.
The method of jackknife repeated replications was used in computing standard errors of prevalence estimates and of logistic regression coefficients to adjust for the design effects introduced by clustering and weighting of observations for differential probabilities of selection and nonresponse.31 The significance of differences between pairs of coefficients was evaluated with z tests based on these corrected standard errors.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONReferences |
|---|
). Among subjects with serious mental illness receiving any treatment, the percentages who received minimally adequate treatment ranged from 7.3% for those with nonaffective psychoses to 48.5% for those with anxiety disorders (see the second set of columns in Table 1).
|
includes the overall percentages of subjects with serious mental illness who did not receive minimally adequate mental health treatment; these percentages ranged from 78.2% among those with mood disorders to 95.9% among those with nonaffective psychoses. On the basis of 1999 US Census Bureau data, these estimates translate to a total of more than 8.5 million individuals with serious mental illness in the US population who do not receive minimally adequate treatment each year.
Treatment in Specific Health Care Sectors
The percentages of patients with serious mental illness and specific disorders receiving mental health treatment in particular health care sectors are shown in Table 2. Relatively few patients with serious mental illness received mental health treatment exclusively in the general medical sector. Higher percentages of subjects received treatment in both the general medical and mental health specialty sectors, while the highest percentages received treatment exclusively in the mental health specialty sector.
|
presents the percentages of patients with serious mental illness whose treatment was minimally adequate. The percentages receiving minimally adequate treatment were smallest among those treated exclusively in the general medical sector and higher among those treated in both the general medical and mental health specialty sectors. With the exception of patients with nonaffective psychoses, the highest percentages receiving minimally adequate treatment were observed among those who were treated exclusively in the mental health specialty sector.
|
presents the percentages of subjects who received any mental health treatment among those with serious mental illness in strata defined by sociodemographic characteristics. Factors significantly associated with receiving any treatment for serious mental illness, also presented in Table 4, included older age (relative to younger age), living in the South (relative to living in the Northeast), and being unemployed or a student (relative to being employed).
|
includes the percentages of patients with serious mental illness who received minimally adequate treatment. Factors significantly associated with receiving minimally adequate care are shown as well, and these factors included being non-Hispanic White (vs Black), being Hispanic (vs non-Hispanic White), and residing in the Northeast (vs the South).
Finally, the percentages of respondents with serious mental illness who did not receive minimally adequate treatment appear in the third set of columns in Table 4. Factors significantly associated with not receiving adequate treatment included being in the youngest age group (vs the oldest) and being Black (vs non-Hispanic White).
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONReferences |
|---|
Second, although adherence to certain recommendations in evidence-based treatment guidelines has been demonstrated to lead to improved clinical outcomes,9–13 we are not aware of studies that have validated our exact definition of minimally adequate treatment. As a result of the nonrandom use of treatments in our study population, we could not investigate whether receipt of our definition of minimally adequate care was associated with improved health outcomes.
Third, we examined the influence of only some patient and health care system factors on type of mental health care received; we did not have the ability to investigate others such as those related to providers. In addition, because of the study's cross-sectional nature, we cannot conclude that factors associated with inadequate treatment are related causally.
Finally, more than 8 years have elapsed since NCS data collection ended in 1992. Dramatic changes have occurred in the intervening years in mental health treatments (e.g., introduction of new medications with potentially greater tolerability) and delivery systems (e.g., greater proportions of individuals receiving mental health treatment under managed care). Although the impact of these changes on the adequacy of treatment for serious mental illness is unknown, emerging evidence from nationally representative data gathered in the late 1990s indicates that inadequate treatment of serious mental illness persists.17 The National Comorbidity Survey Replication, currently under way, will also provide data on any temporal changes in the adequacy of treatment that may have occurred in the past decade.32
In spite of these limitations, the present results shed light on an enormous public health problem. Among patients with serious mental illness, fewer than 1 in every 6 received treatment that could be considered minimally adequate. Considering serious mental illness only on the basis of the 3 types of mental illnesses studied here, this translates into more than 8.5 million individuals with serious mental illness in the United States who do not receive adequate treatment each year.
The percentage of patients receiving minimally adequate treatment was lowest in the extremely vulnerable group with nonaffective psychotic disorders, among whom fewer than 1 in 20 received minimally adequate care. Individuals with chronic psychotic disorders often lack the ability and resources to obtain mental health treatments.33,34 Neuroleptics that are used to treat psychotic disorders have also been shown to be less tolerable than other psychotropic medications.35–37 However, it is possible that patient adherence has increased with the introduction of newer atypical antipsychotic medications with improved side-effect profiles.38,39
Patients with serious mental illness were more likely to receive both any mental health care and minimally adequate treatment in the mental health specialty sector than in the general medical sector. Potential explanations for this finding include the increasing use of primary care providers as "gatekeepers," competing demands experienced by primary care providers for their attention and resources, lack of training in recognition and proper diagnosis of mental disorders, and lack of knowledge concerning optimal treatment regimens among primary care providers.16,40–46 However, it is important to emphasize that improvements in the quality of treatment for serious mental illness appear to be needed in all health care sectors.
Our finding of greater treatment adequacy among patients cared for exclusively by mental health specialists differs somewhat from the results of recent clinical trials indicating that some integrated models of mental health care improve treatment adequacy.9–12 It is possible that actual, "real-world" mental health care involving multiple treaters rather than a single mental health specialist leads to inefficiencies, poor communication among treaters, or other adverse effects on treatment adequacy.
Young adults were less likely to receive any treatment or minimally adequate treatment. In previous studies, this finding has been explained on the basis of a greater dependence of adolescents and young adults on others around them in regard to both initiating and continuing treatment.32,47
Other studies of general medical as well as mental illness have revealed that Blacks have a lower likelihood of receiving quality care.48,49 In this study, we disaggregated the process of receiving adequate treatment and found that Black race/ethnicity was not a significant predictor of whether one successfully accessed any care for serious mental illness. However, among those who successfully accessed some mental health care, Blacks with serious mental illness were 5 times less likely to receive minimally adequate treatment. Further research is necessary to determine the degree to which this finding may result from a greater likelihood among African Americans of leaving treatment prematurely, from treatment bias on the part of providers, or from other factors.50
On the other hand, Hispanics were nearly 5 times more likely than non-Hispanic Whites to receive adequate care for serious mental illness. Greater intensities of treatment among Hispanic patients have been observed in some51–53 but not all previous studies.54 Some have suggested that Hispanic patients are more likely to believe that psychiatric symptoms require professional help and that such symptoms are amenable to treatment.55,56
Previous studies have revealed greater use of any type of mental health treatment in the South than in the Northeast, and this finding has been explained on the basis of a higher likelihood among those in the South than those in the Northeast of reporting psychic distress.57 On the other hand, use of more intensive treatment regimens (e.g., greater frequency of visits) in the Northeast than in the South has also been observed previously and explained in part by the fact that the South contains more rural areas with fewer mental health specialists.58,59
Further research is needed to clarify the reasons for inadequate treatment of serious mental illness in the general population and the reasons for even lower prevalences of adequate treatment in particular subpopulations. On the basis of such information, legislation and cost-effective interventions can be designed and targeted to increase patients' acceptance of and adherence to treatments, as well as clinicians' ability to detect, diagnose, and appropriately treat serious mental illness.60–64 In addition, it will be necessary to establish and apply performance standards or "report cards" (e.g., the Substance Abuse and Mental Health Services Administration's Consumer-Oriented Mental Health Report Card65 or the new National Committee for Quality Assurance standards66) to monitor the effects of future interventions and legislation on the quality of treatment and health outcomes of those with serious mental illness.
|
Acknowledgments |
|---|
We appreciate the helpful comments of Philip Leaf and Bedirhan Ustun on an earlier version of the article.
|
Footnotes |
|---|
Accepted for publication November 7, 2000.
|
References |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONReferences |
|---|
2. Kessler RC, Berglund PA, Walters EE, et al. A methodology for estimating the 12-month prevalence of serious mental illness. In: Manderscheid RW, Henderson RW, eds. Mental Health, United States 1998. Washington, DC: US Government Printing Office; 1998:99–109.
3. Rosenheck RA, Massari L, Frisman L. Who should receive high cost mental health treatment and for how long? Issues in the rationing of mental health care. Schizophr Bull. 1993;19:843–852.
4.
Goldman HH. The obligation of mental health services to the least well off. Psychiatr Serv. 1999;50:659–663.
5.
Rosenheck RA. Principles for priority setting in mental health services and their implications for the least well off. Psychiatr Serv. 1999;50:653–658.
6.
Regier DA, Kaelber CT, Rae DS, et al. Limitations of diagnostic criteria and assessment instruments for mental disorders: implications for research and policy. Arch Gen Psychiatry. 1998;55:109–115.
7.
Spitzer RL. Diagnosis and need for treatment are not the same. Arch Gen Psychiatry. 1998;55:120.
8.
National Advisory Mental Health Council. Health care reform for Americans with severe mental illness: report of the National Advisory Mental Health Council. Am J Psychiatry. 1993;150:1447–1465.
9. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA. 1995;273:1026–1031.[Abstract]
10.
Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry. 1996;53:924–932.
11.
Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression. Arch Gen Psychiatry. 1999;56:1109–1115.
12.
Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care. JAMA. 2000;283:212–220.
13.
Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128–1132.
14. Katz SJ, Kessler RC, Lin E, Wells KB. Medication management of depression in the United States and Ontario. J Gen Intern Med. 1998;13:77–85.[Medline]
15. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophr Bull. 1998;24:11–20.
16.
Wells KB, Katon W, Rogers B, Camp P. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the Medical Outcomes Study. Am J Psychiatry. 1994;151:694–700.
17. Wang PS, Berglund PA, Kessler RC. Recent care of common mental disorders in the US: prevalence and conformance with evidence-based recommendations. J Gen Intern Med. 2000;15:284–292.[Medline]
18. Depression in Primary Care, Volume 2: Treatment of Major Depression. Rockville, Md: Agency for Health Care Policy and Research; 1993.
19. Practice Guideline for Major Depressive Disorder in Adults. Washington, DC: American Psychiatric Association; 1993.
20. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24:1–10.
21. Practice Guideline for the Treatment of Patients With Schizophrenia. Washington, DC: American Psychiatric Association; 1997.
22. Practice Guideline for the Treatment of Patients With Bipolar Disorder. Washington, DC: American Psychiatric Association; 1994.
23. Practice Guideline for the Treatment of Patients With Panic Disorder. Washington, DC: American Psychiatric Association; 1998.
24. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.[Abstract]
25.
Kessler RC, Little RJA, Groves RM. Advances in strategies for minimizing and adjusting for survey nonresponse. Epidemiol Rev. 1995;17:192–204.
26. Composite International Diagnostic Interview (CIDI), Version 1.0. Geneva, Switzerland: World Health Organization; 1990.
27. Spitzer RL, Williams JB, Gibbon M. Structured Clinical Interview for DSM-III-R. New York, NY: Biometrics Research Dept, New York State Psychiatric Institute; 1987.
28. Kessler RC, Wittchen HU, Abelson JM, et al. Methodological studies of the Composite International Diagnostic Interview (CIDI) in the US National Comorbidity Survey. Int J Methods Psychiatr Res. 1998;7:33–55.
29. Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhao S. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med. 1997;27:1079–1089.[Medline]
30. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:1022–1031.[Abstract]
31. Kish L, Frankel MR. Inferences from complex samples. J R Stat Soc. 1974;36:1–37.
32.
Kessler RC, Olfson M, Berglund PA. Patterns and predictors of treatment contact after first onset of psychiatric disorders. Am J Psychiatry. 1998;155:62–69.
33. Attkisson C, Cook J, Karno M, et al. Clinical services research. Schizophr Bull. 1992;18:561–626.
34. Outcasts on Main Street: Report of the Federal Task Force on Homelessness and Severe Mental Illness. Washington, DC: Interagency Council on Homelessness; 1992.
35.
Cramer JA, Rosenheck R. Compliance with medication regimens for psychiatric and medical disorders. Psychiatr Serv. 1998;49:196–210.
36. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry. 1974;31:67–72.[Medline]
37. Van Putten T, May PR. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry. 1978;35:477–480.[Abstract]
38. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51–68.[Medline]
39.
Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156:990–999.
40.
Olfson M, Klerman GL, Pincus HA. The roles of psychiatrists in organized outpatient mental health settings. Am J Psychiatry. 1993;150:625–631.
41. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Arch Gen Psychiatry. 1993;50:85–94.[Abstract]
42. Klinkman MS. Competing demands in psychosocial care: a model for the identification and treatment of mental disorders in primary care. Gen Hosp Psychiatry. 1997;19:98–111.[Medline]
43. Williams JW. Competing demands: does care for depression fit in primary care? J Gen Intern Med. 1998;13:137–139.[Medline]
44. Schwenk TL, Coyne JC, Fechner-Bates S. Differences between detected and undetected patients in primary care and depressed psychiatric patients. Gen Hosp Psychiatry. 1996;18:407–415.[Medline]
45. Eisenberg L. Treating depression and anxiety in primary care. N Engl J Med. 1992;326:1080–1084.[Medline]
46. Narrow WE, Regier DA, Rae DS, Manderscheid RW, Locke BZ. Use of services by persons with mental and addictive disorders. Arch Gen Psychiatry. 1993;50:95–107.[Abstract]
47. Baruch G, Gerber A, Fearon P. Adolescents who drop out of psychotherapy at a community-based psychotherapy center. Br J Med Psychol. 1998;71:233–245.
48. Ayanian JZ, Udvarhelyi IS, Gatsonis CA, Pashos CL, Epstein AM. Racial differences in the use of revascularization procedures after coronary angiography. JAMA. 1993;269:2642–2646.[Abstract]
49. Leaf PJ, Bruce ML, Tischler GL, Freeman DH, Weissman MM, Myers JK. Factors affecting utilization of specialty and general medical mental health services. Med Care. 1988;26:9–26.[Medline]
50. Sellwood W, Tarrier N. Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1994;29:172–177.[Medline]
51. Karno M, Edgerton RG. Perception of mental illness in a Mexican-American community. Arch Gen Psychiatry. 1969;20:233.[Medline]
52. Cheung FK, Snowden LR. Community mental health and ethnic minority populations. Community Ment Health J. 1990;26:277–291.[Medline]
53. Sheffler RM, Miller AG. Demand analysis of mental service use among ethnic subpopulations. Inquiry. 1989;26:202–215.[Medline]
54. Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed patients: clinical observations. Am J Psychother. 1982;36:505–512.[Medline]
55. Karno M, Ross RN, Caper RA. Mental health roles of physicians in a Mexican-American community. Community Ment Health J. 1969;5:62–69.
56. Fabrega H, Rubel AJ, Wallace CA. Working class Mexican psychiatric outpatients. Arch Gen Psychiatry. 1967;16:704–712.[Medline]
57. Mellinger GD, Balter MB, Manheimer DI, Cisin IH, Parry HJ. Psychic distress, life crisis, and use of psychotherapeutic medications. Arch Gen Psychiatry. 1978;35:1045–1052.[Abstract]
58. National Center for Health Statistics. Office visits to psychiatrists: United States 1989–90. Adv Data Vital Health Stat. December 28, 1993; no. 237.
59. Knesper DJ, Wheeler JRC, Pagnucco DJ. Mental health services providers' distribution across counties in the United States. Am Psychol. 1984;39:1424–1434.[Medline]
60.
Regier DA, Hirschfeld RMA, Goodwin FK, Burke JD, Lazar JB, Judd LL. The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis. Am J Psychiatry. 1988;145:1351–1357.
61. Carleton RA, Bazzarre T, Drake J, et al. Report of the expert panel on awareness and behavior change to the board of directors. Circulation. 1996;93:1768–1772.[Medline]
62. Velicer WF, Hughes SL, Fava JL, Prochaska JO, DiClemente CC. An empirical typology of subjects within stage of change. Addict Behav. 1995;20:299–320.[Medline]
63. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333–340.[Abstract]
64. Wang P. Beyond screening: improving the quality of treatment for depression. Harv Rev Psychiatry. 1999;7:177–182.[Medline]
65. Consumer-Oriented Mental Health Report Card. Rockville, Md: Center for Mental Health Services, Substance Abuse and Mental Health Services Administration; 1996.
66. HEDIS 3.0: Narrative: What's in It and Why It Matters. Washington, DC: National Committee for Quality Assurance; 1997.
This article has been cited by other articles:
|
|
 |
|
  P. Roberge, A. Marchand, D. Reinharz, and P. Savard Cognitive-Behavioral Treatment for Panic Disorder With Agoraphobia: A Randomized, Controlled Trial and Cost-Effectiveness Analysis Behav Modif, May 1, 2008; 32(3): 333 - 351. [Abstract] [PDF]
|
|
|
|
 |
|
 S. D. Arnold, L. M. Forman, B. D. Brigidi, K. E. Carter, H. A. Schweitzer, H. E. Quinn, A. B. Guill, J. E. Herndon II, and R. H. Raynor Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors Neuro-oncol, April 1, 2008; 10(2): 171 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Oliva and M. T. Compton A Statewide Crisis Intervention Team (CIT) Initiative: Evolution of the Georgia CIT Program J Am Acad Psychiatry Law, March 1, 2008; 36(1): 38 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Huxley, S. Evans, M. Munroe, and L. Cestari Mental health policy reforms and case complexity in CMHTs in England: replication study Psychiatr. Bull., February 1, 2008; 32(2): 49 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Stein, J. N. Kogan, M. J. Sorbero, W. Thompson, and S. L. Hutchinson Predictors of Timely Follow-Up Care Among Medicaid-Enrolled Adults After Psychiatric Hospitalization Psychiatr Serv, December 1, 2007; 58(12): 1563 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Druss, P. S. Wang, N. A. Sampson, M. Olfson, H. A. Pincus, K. B. Wells, and R. C. Kessler Understanding Mental Health Treatment in Persons Without Mental Diagnoses: Results From the National Comorbidity Survey Replication Arch Gen Psychiatry, October 1, 2007; 64(10): 1196 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Wang, G. E. Simon, J. Avorn, F. Azocar, E. J. Ludman, J. McCulloch, M. Z. Petukhova, and R. C. Kessler Telephone Screening, Outreach, and Care Management for Depressed Workers and Impact on Clinical and Work Productivity Outcomes: A Randomized Controlled Trial JAMA, September 26, 2007; 298(12): 1401 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Fremont, A. S. Young, M. Chinman, P. Pantoja, S. Morton, P. Koegel, G. Sullivan, and D. Kanouse Differences in HIV Care Between Patients With and Without Severe Mental Illness Psychiatr Serv, May 1, 2007; 58(5): 681 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. ALONSO, M. CODONY, V. KOVESS, M. C. ANGERMEYER, S. J. KATZ, J. M. HARO, G. DE GIROLAMO, R. DE GRAAF, K. DEMYTTENAERE, G. VILAGUT, et al. Population level of unmet need for mental healthcare in Europe The British Journal of Psychiatry, April 1, 2007; 190(4): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kroenke, R. L. Spitzer, J. B.W. Williams, P. O. Monahan, and B. Lowe Anxiety Disorders in Primary Care: Prevalence, Impairment, Comorbidity, and Detection Ann Intern Med, March 6, 2007; 146(5): 317 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sareen, A. Jagdeo, B. J. Cox, I. Clara, M. ten Have, S.-L. Belik, R. de Graaf, and M. B. Stein Perceived Barriers to Mental Health Service Utilization in the United States, Ontario, and the Netherlands Psychiatr Serv, March 1, 2007; 58(3): 357 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Weiss Measuring the Impact of Medical Research: Moving From Outputs to Outcomes Am J Psychiatry, February 1, 2007; 164(2): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Wang, A. Patrick, J. Avorn, F. Azocar, E. Ludman, J. McCulloch, G. Simon, and R. Kessler The Costs and Benefits of Enhanced Depression Care to Employers Arch Gen Psychiatry, December 1, 2006; 63(12): 1345 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cook Employment Barriers for Persons With Psychiatric Disabilities: Update of a Report for the President's Commission Psychiatr Serv, October 1, 2006; 57(10): 1391 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Hu, A. Kline, F. Y. Huang, and D. M. Ziedonis Detection of Co-Occurring Mental Illness Among Adult Patients in the New Jersey Substance Abuse Treatment System Am J Public Health, October 1, 2006; 96(10): 1785 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. McHugo, R. E. Drake, M. F. Brunette, H. Xie, S. M. Essock, and A. I. Green Enhancing Validity in Co-occurring Disorders Treatment Research Schizophr Bull, October 1, 2006; 32(4): 655 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Borges, M. E. Medina-Mora, P. S. Wang, C. Lara, P. Berglund, and E. Walters Treatment and Adequacy of Treatment of Mental Disorders Among Respondents to the Mexico National Comorbidity Survey Am J Psychiatry, August 1, 2006; 163(8): 1371 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Wang, P. Berglund, M. Olfson, H. A. Pincus, K. B. Wells, and R. C. Kessler Failure and Delay in Initial Treatment Contact After First Onset of Mental Disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry, June 1, 2005; 62(6): 603 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Wang, M. Lane, M. Olfson, H. A. Pincus, K. B. Wells, and R. C. Kessler Twelve-Month Use of Mental Health Services in the United States: Results From the National Comorbidity Survey Replication Arch Gen Psychiatry, June 1, 2005; 62(6): 629 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Garlow, D. Purselle, and M. Heninger Ethnic Differences in Patterns of Suicide Across the Life Cycle Am J Psychiatry, February 1, 2005; 162(2): 319 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Wang, A. L. Beck, P. Berglund, D. K. McKenas, N. P. Pronk, G. E. Simon, and R. C. Kessler Effects of Major Depression on Moment-in-Time Work Performance Am J Psychiatry, October 1, 2004; 161(10): 1885 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cavazzoni, N. Mukhopadhyay, C. Carlson, A. Breier, and J. Buse Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications The British Journal of Psychiatry, April 1, 2004; 184(47): s94 - s101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. Bijl, R. de Graaf, E. Hiripi, R. C. Kessler, R. Kohn, D. R. Offord, T. B. Ustun, B. Vicente, W. A.M. Vollebergh, E. E. Walters, et al. The Prevalence Of Treated And Untreated Mental Disorders In Five Countries Health Aff., May 1, 2003; 22(3): 122 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dickey, S.-L. T. Normand, R. C. Hermann, S. V. Eisen, D. E. Cortes, P. D. Cleary, and N. Ware Guideline Recommendations for Treatment of Schizophrenia: The Impact of Managed Care Arch Gen Psychiatry, April 1,& |
